44
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Specific Proliferation Towards Myelin Antigens in Patients with Multiple Sclerosis During a Relapse

, , , , &
Pages 45-50 | Published online: 07 Jul 2009
 

Abstract

Whether autoreactive T cells from multiple sclerosis (MS) patients display a certain autoreactive pattern is controversial. In this study, we have analyzed reactivity towards myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), alpha B-crystallin and S100 &#103 antigens in 35 relapsing-remitting MS patients and 12 healthy controls (HC). During relapse, we observed T-specific proliferation towards MBP (15.8%), MOG (38.9%), alpha B-crystallin (11.1%) and S100 &#103 (26.3%) in MS patients. Reactivity to MBP (12%), MOG (28%), alpha B-crystallin (28%) and S100 &#103 (19.2%) was also observed in HC. There were changes in the specific proliferation in consecutive samples obtained from either patients or HC. Such fluctuations did not follow any specific or conservative patterns. Antigen-specific cytokine production was also assessed as a method to evaluate whether there were differences in the qualitative response between MS patients and HC, with negative results. In summary, we show here that the reactivity patterns, as measured by specific proliferation and cytokine production, are similar in RR-MS patients and HC and fluctuate over time.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.